Payment overview · 2025
General Payments
$49.34
3 reported records · 3 companies
Healthcare provider profile · identity verified
Scott H Murphy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORTH VERNON, IN · NPI 1518991991
Verified facts
What the public records show
CMS Open Payments records show Scott H Murphy, M.D. received $49.34 in general payments during 2025 across 3 reported records.
Inspire Medical Systems, Inc. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.44 | 35.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.00 | 34.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.90 | 30.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.34 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
249 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 687 | 174 |
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 492 | 94 |
| Losartan Potassium | Losartan Potassium | 443 | 92 |
| Omeprazole | Omeprazole | 385 | 104 |
| Furosemide | Furosemide | 349 | 70 |
| Potassium Chloride | Potassium Chloride | 326 | 61 |
| Meloxicam | Meloxicam | 255 | 67 |
| Eliquis | Apixaban | 249 | 32 |
| Simvastatin | Simvastatin | 244 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 48 |
| Alendronate Sodium | Alendronate Sodium | 232 | 65 |
| Gabapentin | Gabapentin | 230 | 56 |
| Lisinopril | Lisinopril | 208 | 47 |
| Metformin Hcl | Metformin Hcl | 206 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 41 |
| Tramadol Hcl | Tramadol Hcl | 187 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 38 |
| Clonazepam | Clonazepam | 148 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 38 |
| Montelukast Sodium | Montelukast Sodium | 138 | 36 |
| Trazodone Hcl | Trazodone Hcl | 130 | 31 |
| Warfarin Sodium | Warfarin Sodium | 130 | 14 |
| Allopurinol | Allopurinol | 129 | 30 |
| Alprazolam | Alprazolam | 129 | 23 |
| Prednisone | Prednisone | 120 | 87 |
| Donepezil Hcl | Donepezil Hcl | 119 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 116 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 17 |
| Cefdinir | Cefdinir | 111 | 88 |
| Sucralfate | Sucralfate | 109 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 30 |
| Bumetanide | Bumetanide | 106 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 25 |
| Atenolol | Atenolol | 101 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 29 |
| Carvedilol | Carvedilol | 100 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | 24 |
| Mirtazapine | Mirtazapine | 91 | 18 |
| Sertraline Hcl | Sertraline Hcl | 89 | 15 |
| Benazepril Hcl | Benazepril Hcl | 87 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 19 |
| Ozempic | Semaglutide | 78 | 12 |
| Azithromycin | Azithromycin | 72 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 19 |
| Glimepiride | Glimepiride | 67 | 21 |
| Myrbetriq | Mirabegron | 67 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 15 |
| Divalproex Sodium | Divalproex Sodium | 60 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 15 |
| Spironolactone | Spironolactone | 54 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 31 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 30 |
| Lorazepam | Lorazepam | 46 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Levofloxacin | Levofloxacin | 45 | 31 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 12 |
| Temazepam | Temazepam | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 35 | suppressed |
| Loperamide | Loperamide Hcl | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 24 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Valsartan | Valsartan | 32 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 29 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 11 |
| Galantamine Hbr | Galantamine Hbr | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fluocinonide | Fluocinonide | 21 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 18 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 11 |
| Budesonide Ec | Budesonide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Nystatin | Nystatin | 19 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 12 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Famciclovir | Famciclovir | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.34 · 3 records | Inspire Medical Systems, Inc. | INSPIRE, OTEZLA, PAXLOVID, REPATHA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error